Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Other Investing Activities

Investing cash flows not reported separately.

Evotec SENASDAQ: EVO

Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026

Other investing activities turns positive

Q1 FY2026 other investing activities was €1.02K, compared with -€2.24M a year earlier. Trailing-twelve-month other investing activities was €11.02M.

Context

  • Other investing activities amounted to 0.0% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Other investing activities increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other investing activities holds near €1.02K or moves back toward the trailing-twelve-month quarterly average of €2.76M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.02K-100.0% QoQ
Last fiscal yearDec 2025
€0+100.0% YoY
LTMMar 2026
€11.02M+222.8% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
+100.0%

Other Investing Activities vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +222.8% is the 2nd highest of 5, against a peer median of -30.7%.
  • Other investing activities amounts to 1.5% of revenue for EVO, versus a peer median of 4.1%.
EVO Competitors
Other Investing Activities for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$124.34M USD+38.5%—4.9%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$70M USD+900.0%—77.4%
AZTAAzenta, Inc.LTM Sep 2026$54.5M USD——8.8%
TLRYTilray Brands, Inc.LTM Feb 2026$47.88M USD——4.1%
ALVOAlvotechLTM Mar 2026$38.87M USD-264.8%—6.9%
EVOEvotec SELTM Mar 2026€11.02M EUR+222.8%—1.5%
PCRXPacira BioSciences, Inc.LTM Mar 2026$4.93M USD——0.7%
HROWHarrow Health, Inc.LTM Mar 2026$8K USD-100.0%—0.0%
PHVSPharvaris N.V.LTM Sep 2026€0 EUR———
SDGRSchrödinger, Inc.LTM Sep 2026$0 USD——0.0%
NVCRNovoCure LimitedLTM Mar 2026$0 USD——0.0%
Peer median (excluding EVO) —-30.7%—4.1%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.